The Schall Law Firm has announced a class action lawsuit against FS KKR Capital Corp. (FSK) for alleged securities fraud, urging investors who purchased FSK securities between May 8, 2024, and February 25, 2026, to contact the firm before July 3, 2026. The lawsuit claims FSK made false and misleading statements regarding its portfolio restructuring, valuation process, and quarterly dividend program. Investors are encouraged to join the case to recover losses.

Korean public enterprises are actively expanding their global presence and developing advanced technologies to secure future growth and profitability. Initiatives include Korea Electric Power Corporation's overseas power plant projects and solar power generation in Guam, Korea Gas Corporation's innovative LNG cold and thermal data center technology, and Korea Transportation Safety Authority's autonomous vehicle evaluation system. These efforts also aim to address social roles like climate crisis response and export support.

Barclays and Cantor Fitzgerald have raised their price targets for Applied Materials (AMAT), citing a stronger wafer fab equipment spending cycle and growing confidence in the industry's long-term growth outlook. Barclays increased its target to $590 from $500, while Cantor Fitzgerald boosted its target to $650 from $575, both reiterating an Overweight rating. Both firms believe the semiconductor equipment industry is in the early stages of a multi-year upcycle driven by AI-related investments.

GlobalFoundries and Qualinx have successfully completed Europe’s first fully sovereign semiconductor manufacturing flow for security-sensitive applications, utilizing GF’s FDX platform at their Dresden facility. This milestone enables the development and manufacturing of advanced semiconductors for aerospace, defense, and critical infrastructure entirely within Europe, reinforcing the continent's technological independence. The initiative is supported by the European Chips Act and aims to establish a fully automated trusted manufacturing flow in Dresden by the end of 2026, offering resilient and secure semiconductor solutions to European customers.

Moderna CEO Stéphane Bancel expresses deep concern about Europe's preparedness for another pandemic, especially bioterrorism, highlighting the lack of mRNA manufacturing capacity in continental Europe. He emphasizes Moderna's expanded global infrastructure for quicker vaccine production in a future crisis and discusses the company's return to its pre-pandemic mission of diversifying its mRNA technology into new therapeutic areas like cancer. Bancel confirms Moderna's focus on growing sales by broadening its portfolio beyond COVID-19 vaccines.

SINOPHARM (01099.HK) has formed a strategic partnership with Pfizer, Inc. (PFE.US). The collaboration will focus on "Diflucan" market promotion and service enhancements for Pfizer's future new products. The goal is to integrate resources, optimize channels, and improve operational efficiency to build a stable and efficient industry supply chain.

Piper Sandler has initiated coverage of Danaher (DHR) with a Neutral rating and a $200 price target, adopting a cautious approach to the life science tools sector. While acknowledging the potential of DHR, the firm prefers to wait for new growth catalysts to emerge before recommending more stocks in the sector, citing current headwinds related to biotech and academic spending and China exposure. Piper Sandler only recommends buying Twist Bioscience among the covered companies due to its exposure to next-generation drug discovery.

JPMorgan and Mizuho have raised their price targets for Humana (HUM), with JPMorgan increasing its target to $316 and Mizuho to $390. This adjustment comes as both firms see an improved outlook for the managed care sector, expecting a more stable policy environment and a shift towards focusing on company fundamentals. The analysts believe that regulatory surprises will decrease, allowing investors to prioritize underlying earnings power and pricing recovery in the sector.

Global Payments Inc. (GPN) has been identified as one of billionaire Larry Robbins' top 10 dividend stock picks. While Mizuho analyst Dan Dolev believes concerns about potential Q2 estimate revisions are "overblown" and the company reaffirmed its outlook, TD Cowen recently lowered its price recommendation on GPN to $74 from $86, reiterating a Hold rating due to a more conservative view of previously communicated headwinds. Despite this, the company's message regarding acceleration in the second half of 2026 remains unchanged.

CVS Health (CVS) is identified as one of Billionaire Larry Robbins's top 10 dividend stock picks. The article highlights recent price target increases for CVS from Morgan Stanley and Mizuho, citing improving managed care sector trends and the potential for AI to drive efficiencies. While acknowledging CVS's potential, the article also suggests that certain AI stocks may offer greater upside and less risk.